AIM Biotech
AIM Biotech is a leading bioengineering company, offering scalable, cost-effective 3D cell culture platforms, drug screening services, and customized assay development. By combining model realism and platform simplicity, AIM’s plug-and-play technologies empower drug developers to mimic human biology with precision, delivering clinically-relevant data.
Axol BioScience
Axol Bioscience are leaders in human iPSC products and services for CNS, PNS and cardiac research. Under ISO9001, we manufacture functional hiPSC-derived cells with multi-platform utility for MPS technology, alongside a “one-stop shop” of iPSC lines, services and custom assays.
Exir Bio
Exir Bio’s goal is to accelerate drug discovery, efficacy, and safety assessments by combining nonhuman primate (NHP) in vitro / in vivo models,
replacing, reducing, and refining (3R’s) the use of NHPs – necessary due to the global shortage of NHPs and in accordance with US Modernization Act
2.0.
Exir Bio has access to ~20,000 NHP’s / 8 species across several colonies in the US, all with known origin and bred in captivity per FDA and European
Union requirements.
STEMCELL Technologies
We are the world-leading provider of reagents and services for generating organoid and stem cell-derived models of healthy and diseased human tissues.
Ncardia
For more than a decade, Ncardia has been pioneering innovations in human induced pluripotent stem cells (iPSC).
NETRI
NETRI is an industrial start-up developing innovative technologies for the pharmaceutical industry. Its patented organs-on-chip technologies allow the creation of standardized and predictive human in vitro models.
SynVivo, Inc.
Organ-on-Chip models from SynVivo recreate complex microvasculature including scale, morphology, hemodynamic shear stress, and cellular interactions in a perfused microfluidic chip environment. Validated models include Air Liquid Interface for Lung, Blood-Brain Barrier, Tumor, DIVI, Inflammation.
Hesperos Inc.
Hesperos is accelerating drug discovery by providing safety and efficacy testing services using its Human-on-a-Chip, microphysiological system. This breakthrough technology enables unprecedented preclinical insight bringing better therapies to patients faster without the need for animal testing.
MIMETAS
Mimetas develops high-throughput healthy and diseased organ-on-a-chip models in the OrganoPlate®, a screening-compatible microfluidics platform that supports the recreation of native tissue structures, and their interaction with compounds, signaling factors, disease triggers, and co-cultured cell types.